Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(40,834) | $(29,511) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 32 | 27 |
| Stock-based compensation expense | 10,602 | 5,315 |
| Accretion of discount on investment securities | (1,218) | (1,899) |
| Amortization of right-of-use operating lease assets | 44 | 106 |
| Loss on investment in former related party | 302 | (5) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's D&A?
- Dianthus Therapeutics (DNTH) reported D&A of $32K in Q1 2026.
- How has Dianthus Therapeutics's D&A changed year-over-year?
- Dianthus Therapeutics's D&A increased by 18.5% year-over-year, from $27K to $32K.
- What is the long-term trend for Dianthus Therapeutics's D&A?
- Over 3 years (2021 to 2024), Dianthus Therapeutics's D&A has grown at a -63.8% compound annual growth rate (CAGR), from $2.02M to $96K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Dianthus Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude